EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Efficacy and safety of levosimendan in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: The LEVOCEST trial

Francisco Bosa Ojeda, Corabel Méndez Vargas iD, Juan Lacalzada Almeida, María M Izquierdo Gómez, Alejandro Jiménez Sosa, Consuelo Rodríguez Jiménez, Alejandro Sánchez-Grande Flecha, Marta Bosa Santana, Geoffrey Yanes Bowden

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.31267 ↗

At a glance

Randomisierte kontrollierte Studie in Catheterization and Cardiovascular Interventions, 2024. Written by Francisco Bosa Ojeda and 8 co-authors. Institution: Department of Interventional Cardiology, University Hospital of the Canary Islands, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain. Major MEDLINE topics: Percutaneous Coronary Intervention, Simendan, ST Elevation Myocardial Infarction, Stroke Volume. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Orion Corporation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Primary angioplasty is the standard procedure for patients with ST‐segment elevation myocardial infarction (STEMI). However, myocardial reperfusion results in additional cell damage. Levosimendan, due to its pleiotropic effects, may be a therapeutic alternative to prevent this damage. The objective of this study was to evaluate whether this drug can reduce infarct size in patients with STEMI.

Methods

Patients were randomized to receive a 24‐h infusion of either levosimendan (0.1 μg/kg/min) or placebo after the primary angioplasty. The main objective was to assess the size of the infarct by cardiac resonance at 30 days and 6 months after the event. Other variables such as left ventricular ejection fraction (LVEF) and adverse ventricular remodeling (AVR) were assessed by speckle‐tracking echocardiography and magnetic resonance. Major adverse cardiovascular events (MACE) were also collected.

Results

157 patients were analysed (levosimendan, n = 79; placebo, n = 78). We found that after 6 months, patients treated with levosimendan had a greater reduction in infarct size (13.19% ± 9.5% vs.11.79% ± 9%, p = 0.001), compared with those in the placebo group (13.35% ± 7.1% vs. 13.43% ± 7.8%, p = 0.38). There were no significant differences in MACE between both groups.

Conclusions

Levosimendan is a safe and effective therapeutic option for reducing infarct size in patients with STEMI.

Subjects

MeSH terms (MEDLINE)

Percutaneous Coronary InterventionSimendanST Elevation Myocardial InfarctionStroke VolumeVentricular Function, LeftVentricular RemodelingAgedFemaleHumansMaleMiddle AgedCardiotonic AgentsDouble-Blind MethodInfusions, IntravenousMyocardiumProspective StudiesPyridazinesRecovery of FunctionTime FactorsTreatment Outcome

Author keywords

ST‐segment elevationlevosimendanmyocardial infarctionprimary angioplastyreperfusion injury

Substances

Cardiotonic AgentsPyridazinesSimendan

Authors and institutions

  • Department of Interventional Cardiology, University Hospital of the Canary Islands, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain.
  • Department of Cardiology, University Hospital of the Canary Islands, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain.
  • Research Unit, University Hospital of the Canary Islands, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain.
  • Clinical Pharmacology Service, Clinical Research and Clinical Trials Unit of the University Hospital of the Canary Islands, Canary Islands, Spain.
  • Emergency Department, University Hospital Nuestra Señora de Candelaria, Canary Islands, Spain.

ORCID profiles: Corabel Méndez Vargas

Funding

  • Orion Corporation

Cite

APA

Bosa Ojeda, F., Méndez Vargas, C., Lacalzada Almeida, J., Izquierdo Gómez, M. M., Jiménez Sosa, A., Rodríguez Jiménez, C., Sánchez-Grande Flecha, A., Bosa Santana, M., & Yanes Bowden, G. (2024). Efficacy and safety of levosimendan in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: The LEVOCEST trial. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31267

Vancouver

Bosa Ojeda F, Méndez Vargas C, Lacalzada Almeida J, Izquierdo Gómez MM, Jiménez Sosa A, Rodríguez Jiménez C, et al. Efficacy and safety of levosimendan in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: The LEVOCEST trial. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31267

BibTeX
@article{BosaOjeda2024,
  author = {Bosa Ojeda, Francisco and Méndez Vargas, Corabel and Lacalzada Almeida, Juan and Izquierdo Gómez, María M and Jiménez Sosa, Alejandro and Rodríguez Jiménez, Consuelo and Sánchez-Grande Flecha, Alejandro and Bosa Santana, Marta and Yanes Bowden, Geoffrey},
  title = {Efficacy and safety of levosimendan in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: The LEVOCEST trial},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.31267}
}
Start for free →